Sugi Predict

Sugi Predict / Targets / NLK

NLK

Serine/threonine-protein kinase NLK · Q9UBE8 · NLK on Sugi Atlas →

9,517 patent compounds predicted against NLK, 7,635 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL858213 SCHEMBL858213 0.64 11/20
SCHEMBL2292717 SCHEMBL2292717 0.60 10/20
SCHEMBL2289246 SCHEMBL2289246 0.65 9/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2291538) 0.64 9/20
SCHEMBL857882 SCHEMBL857882 0.50 6/20
SCHEMBL725132 SCHEMBL725132 0.41 5/20
SCHEMBL1172280 SCHEMBL1172280 0.66 4/20
SCHEMBL2205672 SCHEMBL2205672 0.65 4/20
SCHEMBL723904 SCHEMBL723904 0.42 4/20
SCHEMBL422865 SCHEMBL422865 1.00 3/20
SCHEMBL1347618 SCHEMBL1347618 1.00 3/20
SCHEMBL423761 SCHEMBL423761 0.84 3/20
SCHEMBL424288 SCHEMBL424288 0.80 3/20
SCHEMBL424886 SCHEMBL424886 0.79 3/20
SCHEMBL422803 SCHEMBL422803 0.78 3/20
SCHEMBL420726 SCHEMBL420726 0.78 3/20
SCHEMBL1380283 SCHEMBL1380283 0.77 3/20
SCHEMBL422817 SCHEMBL422817 0.74 3/20
SCHEMBL1383067 SCHEMBL1383067 0.73 3/20
SCHEMBL424833 SCHEMBL424833 0.73 3/20

Clinical trials — most relevant to NLK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of NSK-SD (Nattokinase) on Blood Pressure PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis PHASE2RECRUITING
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Biological Effects of Quercetin in COPD Phase II PHASE2UNKNOWN
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors PHASE1UNKNOWN
A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer PHASE1RECRUITING
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma nanCOMPLETED
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NLK binder may also engage these)

ProteinNameSimilarity
O54949 — 1.000 O54949 →
E1BMN8 — 1.000 E1BMN8 →
D3ZSZ3 — 1.000 D3ZSZ3 →
E2QWQ2 — 1.000 E2QWQ2 →
B1H3E1 — 0.963 B1H3E1 →
PRKD1 Serine/threonine-protein kinase D1 0.960 landscape →
Q8BZ03 — 0.954 Q8BZ03 →
Q9WTQ1 — 0.954 Q9WTQ1 →
Q5XIS9 — 0.954 Q5XIS9 →
Q640Q5 — 0.954 Q640Q5 →
Q17IE8 — 0.953 Q17IE8 →
Q8QGV6 — 0.952 Q8QGV6 →
Q62101 — 0.952 Q62101 →
MAPKAPK2 MAP kinase-activated protein kinase 2 0.951 landscape →
PRKD2 Serine/threonine-protein kinase D2 0.951 landscape →
O88506 — 0.951 O88506 →
O42099 — 0.951 O42099 →
A0A8I5ZNK2 — 0.950 A0A8I5ZNK2 →
Q6P9R2 — 0.949 Q6P9R2 →
P33674 — 0.949 P33674 →
Q58A45 — 0.949 Q58A45 →
CSNK2A1 Casein kinase II subunit alpha 0.949 landscape →
Q03351 — 0.949 Q03351 →
Q7XKA8 — 0.948 Q7XKA8 →
STK39 STE20/SPS1-related proline-alanine-rich protein kinase 0.947 landscape →
Q1ECX4 — 0.947 Q1ECX4 →
Q9Z1W9 — 0.946 Q9Z1W9 →
Q66KH9 — 0.946 Q66KH9 →
ROR1 Inactive tyrosine-protein kinase transmembrane receptor ROR1 0.946 landscape →
Q863I2 — 0.945 Q863I2 →